KRAS野生型的转移性结直肠癌的一线治疗探讨(王志强).pptVIP

三药方案的有效率和切除率FOLFIRIFOLFOXIRIResponserateR0resectionrate(liver-limiteddisease)FOLFIRIFOLFOXIRIFalconeA,etal.JClinOncol2007;25:1670–1676Patients(%)Patients(%)GONOstudyp0.0001p=0.01734.060.012.036.0病例二:不可切除的转移性结直肠癌一线治疗方案的选择1. FOLFOX/XELOX+贝伐珠单抗2. FOLFIRI/XELIRI+贝伐珠单抗3. FOLFOX+西妥昔单抗4. XELOX+西妥昔单抗FOLFIRI/XELIRI+西妥昔单抗贝伐珠单抗在III期随机试验中的疗效治疗方案n中位PFS(月)中位OS(月)RR

(%)FOLFOX/CAPOX±贝伐珠单抗1 1,4009.4vs8

HR=0.8321.3vs19.8

HR=0.8938vs38IFL±贝伐珠单抗2 81310.6vs6.2

HR=0.5420.3vs15.6

HR=0.6645vs355-FU/LV±贝伐珠单抗3(汇聚分析) 241